Clinical Trials · NCT04478708

Single and Multiple Ascending Dose Study of AMG 133 in Participants With Obesity

Name: Single and Multiple Ascending Dose Study of AMG 133 in Participants With Obesity
Creator: Peptide Science Daily
License: https://clinicaltrials.gov/about-site/terms-conditions

CompletedPhase 1Maridebart cafraglutide

Phase: Phase 1
Recruitment status: Completed
Sponsor: Amgen
Enrollment: 110
Start date: Aug 2020
Locations: 3 sites, United States
Primary endpoint: Number of Participants With Treatment-emergent Adverse Events (TEAEs)

View Maridebart-Cafraglutide compound reference